user avatar
H. Jack West, MD, FASCO
@JackWestMD
VP of Global Medical Affairs @SMMT_Tx; Founder,@CancerGRACE; fmr author/ed @UptoDate. Tech-friendly for an old guy. Likes/RTs ≠ endorsement
Chicago, IL
Joined April 2009
Posts
  • user avatar
    Is there anyone at #ASCO22, or not, who thinks hotel door bag drop of pharma advertisements is anything but a tone-deaf, disdainful waste of money & paper? To me, it symbolizes an utter lack of ability to adapt to changing times. Don't highlight you're dinosaurs in an Ice Age.
  • user avatar
    🚨 Big changes afoot! I'm proud to announce that I've joined Summit Therapeutics (@summitplc) as VP of Clinical Development! I look forward to my colleagues learning more about the company & ivonescimab. No more commentary from me on new data, but I'll contribute as I can.
  • user avatar
    KRAS G12C inhibitor sotorasib combined with pembrolizumab for KRAS G12C+ adv NSCLC led to prohibitive hepatotoxicity that required aggressive dose reduction of sotorasib. We've seen similar probs with some other targeted therapies combined w/immunotherapies. #WCLC22
  • user avatar
    I'm not sure I can envision a more intellectually dishonest figure than one that has the y-axis extend from 99 to 100 to show a huge separation of curves. 🙄 Really misrepresents the actual findings.
    Psoriasis Risk With Immune Checkpoint Inhibitors @JAMADerm doi.org/10.1001/jamade… ❓What is the risk to develop psoriasis with ICI 🔎135 230 pts 👉2-fold increased, 0.5 vs 0.2% 🧐Uncommon, but be aware & provide optimal care @myESMO
  • user avatar
    Replying to @Tony_Calles @BrendonStilesMD and 8 others
    Not current. My quick algorithm: 1) Check driver mut'ns & PD-L1 2) if EGFR, ALK, ROS1, or BRAF V600E+ -> targeted Rx 3) o/w, if PD-L1 <50% -> chemo/IO (KN189 for nonsquam, KN407 for squam); if PD-L1 > or =50%, pembro mono unless high tumor burden/declining PS (if so, chemo/IO 1L)
  • user avatar
    Dr. R. Govindan presents update on ph1 of KRAS G12C mut’n inhib AMG 510 in NSCLC. Impressive results: well tolerated, w/no DLTs up to 960 mg QD; DCR 96%, ORR 48% in evaluable pts. IMO, this is a turning point of effective Rx against tough & common mut’n. #WCLC19 #OncoAlert #LCSM
  • user avatar
    Amazing & wonderful to see median surv out at 30+ mo for pts w/high tumor PD-L1 receiving 1st line pembro. That's 28-30% of pts who add to those w/driver mut'ns, & it means we're at point where we're nearing a majority of pts w/adv NSCLC having expectation of living years. #LCSM
    Updated analysis of KEYNOTE-024 - pembrolizumab vs platinum-based chemo for advanced NSCLC bit.ly/2LUcZ3W #lcsm #immunoonc
  • user avatar
    Celebrating my lovely wife's birthday tonight. 🎂🎈For the record, I didn't marry someone 25 years younger than me. Amazingly, we're the same age, but no question who wears it better.
  • user avatar
    My wife & I are thinking of getting away this weekend, spending it in our guest room for a change of pace.
  • user avatar
    I'm so tired of having to reschedule patients for further days out after the lab fails to deliver molecular marker results in the expected time. 😞 The results are the focus of the visit! The most imprecise thing about precision medicine is the turnaround time.
  • user avatar
    Ladies & gentlemen, my stepdaughter is amazing! Congrats, Mya!!🔥🔥
    Mya Lauzon locks in her second-straight 9.9+ score on beam with a 9.925! #GoBears 🐻 | #OneDayBetter
    00:00
  • user avatar
    My top 5 #ASCO18 abstracts to check in advanced NSCLC track, both a list & a video w/my explanation giving context for their significance. Check it out. Next will be my top 5 for stage I-III NSCLC, SCLC, & meso. bit.ly/JW5AdvNSCLC (pls like, comment, & subscribe!) #LCSM
  • user avatar
    "Maybe one day, once I have decades of experience as a doctor and further training in my area of specialization, I will be able to speak about health matters with the tone of authority of the average naturopath." How to Counter the Circus of Pseudoscience nyti.ms/2Eb5ArT
  • user avatar
    Interesting piece, suggesting we need to take COVID-19 VERY seriously & cancel everything in the foreseeable future. theatlantic.com/ideas/archive/…